18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1339-1346

  Chitneni, Satish K ^a   Bida, Gerald T ^a   Yuan, Hong ^b   Palmer, Gregory M ^a   Hay, Michael P ^c   Melcher, Thorsten ^d   Wilson, William R ^c   Zalutsky, Michael R ^a   Dewhirst, Mark W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d VARIAN MEDICAL SYSTEMS   (United States)

Author keywords

18F EF5; Hypoxia; PET; Prodrug; Response; SN30000

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3, PENTAFLUOROPROPYL)ACETAMIDE F 18; PLACEBO; PRODRUG; RADIOPHARMACEUTICAL AGENT; SN 3000; UNCLASSIFIED DRUG; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2-(2-NITRO-1H-IMIDAZOL-1-YL)-N-(2,2,3,3,3-PENTAFLUOROPROPYL)ACETAMIDE; AMINE OXIDE; CEN 209; CEN-209; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ETANIDAZOLE; FLUORINATED HYDROCARBON; FLUORINE; TRIAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG UPTAKE; EARLY INTERVENTION; EX VIVO STUDY; EXPERIMENTAL RAT; FEASIBILITY STUDY; FEMALE; HYPOXIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; NONHUMAN; OXYGEN AFFINITY; OXYGEN SATURATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RAT; SPECTROSCOPY; TUMOR XENOGRAFT; 18F-EF5; ANIMAL; CELL HYPOXIA; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG EFFECT; HUMAN; LUNG TUMOR; PATHOLOGY; PET; RADIATION EXPOSURE; RESPONSE; SCINTISCANNING; SN30000; TREATMENT OUTCOME;

18F-EF5; HYPOXIA; PET; PRODRUG; RESPONSE; SN30000;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIC N-OXIDES; ETANIDAZOLE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; HYDROCARBONS, FLUORINATED; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PRODRUGS; RATS; TREATMENT OUTCOME; TRIAZINES;

EID: 84881394557     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.116293     Document Type: Article

References (30)

1. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol. 2004;14:198-206.
2. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8:425-437.
3. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-732.
4. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26:225-239.
5. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49(suppl 2):129S-148S.
6. Evans SM, Fraker D, Hahn SM, et al. EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2006;64:922-927.
7. Evans SM, Judy KD, Dunphy I, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res. 2004;10:8177-8184.
8. Komar G, Seppaenen M, Eskola O, et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med. 2008;49:1944-1951.
9. Koch CJ, Scheuermann JS, Divgi C, et al. Biodistribution and dosimetry of 18F-EF5 in cancer patients with preliminary comparison of 18F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl MedMol Imaging. 2010;37:2048-2059.
10. Lin LL, Silvoniemi A, Stubbs JB, et al. Radiation dosimetry and biodistribution of the hypoxia tracer 18F-EF5 in oncologic patients. Cancer Biother Radiopharm. 2012;27:412-419.
11. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393-410.
12. Hicks KO, Siim BG, Jaiswal JK, et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res. 2010;16:4946-4957.
13. Wang J, Foehrenbacher A, Su J, et al. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia. Clin Cancer Res. 2012;18:1684-1695.
14. Dolbier WR, Li AR, Koch CJ, Shiue CY, Kachur AV. 18F-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot. 2001;54:73-80.
15. Chitneni SK, Bida GT, Dewhirst MW, Zalutsky MR. A simplified synthesis of the hypoxia imaging agent 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-18F- pentafluoropropyl)-acetamide (18F-EF5). Nucl Med Biol. 2012;39:1012-1018.
16. Palmer GM, Viola R, Schroeder T, Yarmolenko P, Dewhirst M, Ramanujam N. Quantitative diffuse reflectance and fluorescence spectroscopy: tool to monitor tumor physiology in vivo. J Biomed Opt. 2009;14:024010.
17. Riesterer O, Honer M, Jochum W, Oehler C, Ametamey S, Pruschy M. Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res. 2006;12:3518-3524.
18. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005;23:79-87.
19. Rischin D, Peters LJ, O'Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010;28: 2989-2995.
20. Rischin D, Hicks RJ, Fisher R, et al. Prognostic significance of 18F-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group study 98.02. J Clin Oncol. 2006;24:2098-2104.
21. Beck R, Roeper B, Carlsen JM, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med. 2007;48:973-980.
22. Kim IH, Brown JM. Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int J Radiat Oncol Biol Phys. 1994;29:493-497.
23. Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res. 2009;172:653-665.
24. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in nonsmall-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-2657.
25. Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:8362-8370.
26. Novello S, Giaj Levra M, Vavala T. Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: a review of existing evidence. Crit Rev Oncol Hematol. 2012;83:208-215.
27. Nehmeh SA, Lee NY, Schroder H, et al. Reproducibility of intratumor distribution of 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys.2008;70:235-242.
28. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancer using 18F-fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391-398.
29. Vera P, Bohn P, Edet-Sanson A, et al. Simultaneous positron emission tomography (PET) assessment of metabolism with 18F-fluoro-2-deoxy-D-glucose (FDG), proliferation with 18F-fluoro-thymidine (FLT), and hypoxia with 18Ffluoromisonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol. 2011;98: 109-116.
30. Vishwanath K, Klein D, Chang K, Schroeder T, Dewhirst MW, Ramanujam N. Quantitative optical spectroscopy can identify long-term local tumor control in irradiated murine head and neck xenografts. J Biomed Opt. 2009;14: 054051.